Table 2- VIP and VIM studies: percentage of eyes with loss <3 lines in the ETDRS chart.
Table 2- VIP and VIM studies: percentage of eyes with loss <3 lines in the ETDRS chart.
|
Study
|
MTRI
verteporfin |
MTRI Placebo |
p |
| VIP 12 months | 49% | 45% | Ns |
| VIP 24 months | 45% | 32% | 0.032 |
| VIM 12 months 300 mw/cm2 |
86% | 53% | 0.002 |
| VIM 12 Months 600 mw/cm2 |
72% | 53% |
0.08 |
| VIM 24 months 300 mwcm2 |
74% | 38% | 0.003 |
| VIM 24 months 600 mwcm2 |
47% | 38% | 0.45 |